# Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Source: https://onco.cc/trials/nct07109414/  
OnCo record `nct07109414` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of NP-G2-044 in ovarian cancer, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) is a phase 2/3 interventional study registered as NCT07109414 by Novita Pharmaceuticals, Inc., with 380 participants enrolled, started 2025-12-29 and due to reach its primary completion in 2028-10-25. Interventions recorded: NP-G2-044 and PLD.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07109414
- Phase: 2/3
- Setting: Randomized Phase 2/3 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
- Sponsor: Novita Pharmaceuticals, Inc.
- Enrolled: 380

## Sources

- ClinicalTrials.gov NCT07109414: https://clinicaltrials.gov/study/NCT07109414

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/nct07109414.json